Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) – Research analysts at Jefferies Financial Group upped their FY2022 earnings per share estimates for Ultragenyx Pharmaceutical in a research note issued on Wednesday, February 1st. Jefferies Financial Group analyst M. Raycroft now anticipates that the biopharmaceutical company will earn ($9.22) per share for the year, up from their prior estimate of ($9.25). The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($8.84) per share. Jefferies Financial Group also issued estimates for Ultragenyx Pharmaceutical's Q4 2022 earnings at ($2.25) EPS, Q1 2023 earnings at ($1.45) EPS, Q2 2023 earnings at ($1.41) EPS, Q3 2023 earnings at ($1.45) EPS, FY2023 earnings at ($5.64) EPS, FY2024 earnings at ($4.59) EPS, FY2025 earnings at ($5.19) EPS, FY2026 earnings at $0.35 EPS and FY2027 earnings at $12.32 EPS.
Get Ultragenyx Pharmaceutical alerts:A number of other research analysts also recently issued reports on RARE. Cowen lowered their price target on Ultragenyx Pharmaceutical from $86.00 to $65.00 in a report on Thursday, November 3rd. Credit Suisse Group lowered their price target on Ultragenyx Pharmaceutical from $105.00 to $96.00 and set an "outperform" rating on the stock in a report on Thursday, November 3rd. Morgan Stanley lowered their price target on Ultragenyx Pharmaceutical from $100.00 to $95.00 and set an "overweight" rating on the stock in a report on Friday. SVB Leerink lowered their price target on Ultragenyx Pharmaceutical from $115.00 to $108.00 and set an "outperform" rating on the stock in a report on Thursday, November 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $82.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, December 30th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $91.69.
Ultragenyx Pharmaceutical Trading Down 3.4 %
NASDAQ RARE opened at $45.73 on Monday. The stock has a market cap of $3.21 billion, a P/E ratio of -4.70 and a beta of 0.96. Ultragenyx Pharmaceutical has a 12 month low of $33.36 and a 12 month high of $85.53. The stock's fifty day moving average price is $43.04 and its 200-day moving average price is $43.52.Institutional Trading of Ultragenyx Pharmaceutical
Several institutional investors have recently made changes to their positions in RARE. RTW Investments LP grew its position in shares of Ultragenyx Pharmaceutical by 71.9% during the third quarter. RTW Investments LP now owns 2,359,996 shares of the biopharmaceutical company's stock worth $97,727,000 after purchasing an additional 986,712 shares in the last quarter. State Street Corp grew its holdings in Ultragenyx Pharmaceutical by 26.1% during the 2nd quarter. State Street Corp now owns 2,457,308 shares of the biopharmaceutical company's stock valued at $146,603,000 after buying an additional 508,624 shares in the last quarter. Wellington Management Group LLP grew its holdings in Ultragenyx Pharmaceutical by 17.1% during the 1st quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company's stock valued at $244,747,000 after buying an additional 492,842 shares in the last quarter. BlackRock Inc. grew its holdings in Ultragenyx Pharmaceutical by 9.2% during the 3rd quarter. BlackRock Inc. now owns 3,927,639 shares of the biopharmaceutical company's stock valued at $162,645,000 after buying an additional 330,055 shares in the last quarter. Finally, Eventide Asset Management LLC purchased a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $12,663,000. Hedge funds and other institutional investors own 93.17% of the company's stock.
Insider Transactions at Ultragenyx Pharmaceutical
In other news, CAO Theodore Alan Huizenga sold 2,031 shares of the firm's stock in a transaction dated Wednesday, December 21st. The stock was sold at an average price of $43.96, for a total value of $89,282.76. Following the transaction, the chief accounting officer now owns 16,197 shares of the company's stock, valued at $712,020.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 6.70% of the company's stock.
Ultragenyx Pharmaceutical Company Profile
(Get Rating)
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.
Featured Stories
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.